More or Less · Topics · Episode #168
The Peptide Gray Market Is Going Legit: the FDA Is Moving Compounds Back Into Pharmacies
Clip from the full recording, 52:52–57:44 · download mp4
Brit demands real answers on legality and cancer risk, and Matt explains how a chaotic, unregulated peptide gray market — bodybuilder recommendations and all — is in the middle of being folded back into FDA-inspected compounding pharmacies.
Brit drops the good-natured framing and asks pointed questions: are these substances even legal, and what’s her actual cancer risk? Matt explains the regulatory history: three years ago, the FDA moved many popular peptides out of standard compounding pharmacies, which created a chaotic, unregulated gray market with unreliable sourcing and testing — the “research use only” loophole era, where, as Matt bluntly puts it, “your gym bro is recommending these compounds to you.” That’s now reversing: a month and a half ago, the FDA’s compounding advisory body (PCAC) recommended six out of seven reviewed peptides — including BPC-157 and TB-500, nicknamed the “Wolverine stack” for tissue repair — move back into regulated compounding pharmacies, with another twelve under review for February.
Matt frames this as good news across the board: it means reliable sourcing, FDA and state inspection, proper doctor oversight, and real patient monitoring, replacing the current free-for-all. On the specific cancer question, he defers to NoHo’s staff oncologist rather than offering a casual answer himself. He also details NoHo’s business model directly: a roughly $300/month membership that includes an initial peptide, doctor consultations to build a personalized protocol based on goals (sleep, cognition, body composition), and ongoing sourcing and monitoring — with Matt explicitly warning listeners not to self-dose based on things they read on the internet.
Key points
- Three years ago, the FDA moved many popular peptides out of compounding pharmacies, creating an unregulated gray market under a 'research use only' label with unreliable sourcing and testing.
- About a month and a half before this recording, the FDA's compounding advisory body (PCAC) recommended six of seven reviewed peptides move back into regulated compounding pharmacies; another twelve are under review for February.
- BPC-157 and TB-500 — nicknamed the 'Wolverine stack' for tissue repair — are among the peptides moving back toward regulated, FDA/state-inspected compounding.
- Matt argues the regulatory shift replaces an unreliable, 'gym bro' recommendation culture with doctor oversight, quality control, and reliable sourcing.
- On cancer risk specifically, Matt defers to NoHo's staff oncologist rather than giving a personal answer, and stresses patients should consult a doctor rather than self-dosing from internet research.
- NoHo's business model: roughly $300/month membership including an initial peptide, doctor consultations, a personalized protocol based on patient goals, and ongoing sourcing and monitoring.
Where they landed
Quotes
“What are these legal? What's happening here? Like, am I gonna get cancer?”— Brit
“Six out of the seven that they proposed are moving back into compounding pharmacies... like BPC-157.”— Matt
“This gray market is about to go back into FDA inspected facilities and state inspected facilities, where they can be reliably compounded.”— Matt
“Don't take anything you read on the internet... you should go see a doctor.”— Matt
Suggested tweets
Brit Morin's blunt peptide question for Matt Mazzeo: "Are these legal? Am I gonna get cancer?" His answer involves a three-year-old FDA decision that's now quietly reversing.
Tweet this →BPC-157 and TB-500 — nicknamed the "Wolverine stack" — are among the peptides the FDA is moving back into regulated compounding pharmacies after years in a gray market.
Tweet this →Matt Mazzeo's blunt description of the current peptide market: "Your gym bro is recommending these compounds to you." That's about to change.
Tweet this →All topics · Full episode #168 + transcript · Subscribe on YouTube · Spotify